Speakers Dr. Thomas Tu, Dr. Andrew Klein, Dr. Wissam Jabber, Dr. Ken Rosenfield, Dr. Rachel Rosovsky, Dr. Victor Tapson, and Dr. Catalin Toma highlight the need for randomized controlled trials on treatment of intermediate-high risk pulmonary embolism.